Indeed, EZM2302, a CARM1-specific inhibitor, inhibits CARM1-mediated GATAD2A methylation, GATAD2A chromatin binding, transcriptional activation of cell cycle genes, cell cycle progression, and eventually tumor growth. This evidence concerns the gene CARM1 and neoplasm.